Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Metastasis02:30

Metastasis

6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging community and facility care: cost-effectiveness of implementing 2019 childhood pneumonia management guidelines in India.

Cost effectiveness and resource allocation : C/E·2026
Same author

Candida Species Isolated From ICU Bloodstream Infections: Molecular Epidemiology, Antifungal Resistance, and Virulence Profiling.

Cureus·2025
Same author

Role of tankyrase scaffolding in the β-catenin destruction complex and WNT signaling.

bioRxiv : the preprint server for biology·2025
Same author

Sexual Harassment among Female Healthcare Workers, its Consequences and Barriers in Seeking Help in India's Health Sector.

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine·2025
Same author

A Masquerading Case of <i>Cryptococcus neoformans</i>.

The Journal of the Association of Physicians of India·2025
Same author

LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Related Experiment Video

Updated: Jan 1, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.

Shasha Ruan1,2, Ming Lin1,3, Yong Zhu4

  • 1Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.

Cancer Research
|December 18, 2019
PubMed
Summary
This summary is machine-generated.

Targeting Integrin β4 (ITGB4) with immunotherapy, including dendritic cells and bispecific antibodies, effectively reduced tumor growth and metastasis in mouse models. Combining these strategies with anti-PD-L1 enhanced efficacy and reduced cancer stem cells without toxicity.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.6K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K

Related Experiment Videos

Last Updated: Jan 1, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.6K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.4K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Stem Cell Biology

Background:

  • Integrin β4 (ITGB4) plays a crucial role in regulating cancer stem cells (CSCs).
  • Targeting ITGB4 presents a novel immunotherapeutic strategy for CSCs.
  • Existing immunotherapies may benefit from strategies that also target CSCs.

Purpose of the Study:

  • To develop and evaluate immunologic strategies targeting ITGB4 for cancer therapy.
  • To assess the efficacy of ITGB4-targeted immunotherapies in reducing CSCs and bulk tumor populations.
  • To investigate the potential of combining ITGB4-targeted therapies with anti-PD-L1.

Main Methods:

  • Developed ITGB4 protein-pulsed dendritic cells (ITGB4-DC) for vaccination.
  • Developed anti-CD3/anti-ITGB4 bispecific antibody (ITGB4 BiAb)-armed T cells for adoptive transfer.
  • Assessed immunotherapies in 4T1 mammary tumor and SCC7 head and neck squamous carcinoma mouse models, with and without anti-PD-L1 treatment.
  • Evaluated tumor growth, metastasis, CSC reduction, tumor-initiating capacity, and toxicity.

Main Results:

  • Both ITGB4-DC and ITGB4 BiAb-T cell immunotherapies significantly inhibited local tumor growth and metastasis in both models.
  • Combination therapy with anti-PD-L1 significantly enhanced the efficacy of ITGB4-targeted immunotherapies.
  • ITGB4-targeted immunotherapies induced T-cell cytotoxicity against CSCs and non-CSCs expressing ITGB4, and immune plasma-mediated killing of CSCs.
  • Treatments reduced ITGB4-high CSCs and their tumor-initiating capacity, with no observed toxicity.
  • Specificity was confirmed using ITGB4 knockout and ITGB4-negative cell lines.

Conclusions:

  • Immunologic targeting of ITGB4, using either ITGB4-DC or ITGB4 BiAb-T cells, is a promising strategy against CSCs and bulk tumors.
  • Combining ITGB4-targeted immunotherapy with anti-PD-L1 blockade further enhances therapeutic outcomes.
  • ITGB4-targeted immunotherapy demonstrates potential for broad application across various tumor types expressing ITGB4 on CSCs.